It's the best of two worlds: 5% rotating categories, plus fixed bonus categories like dining and some travel. This card is lucrative and ideal for optimizers who don't mind putting in some work to ...

Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from ...

Tolebrutinib slows disability progression in adults with nonrelapsing secondary progressive multiple sclerosis (MS).

Dr Pavan Bhargava gives insights on earlier diagnosis, ocrelizumab safety in pregnancy, and promising anti-aging effects of diet in RRMS.

Researchers at the VIB-UGent Center for Medical Biotechnology have discovered a promising strategy to improve treatment ...

Tolebrutinib, a brain-penetrant BTK inhibitor, may fill a significant unmet need by delaying disability progression in patients with non-relapsing secondary progressive multiple sclerosis.

Two researchers win the Breakthrough Prize in Life Sciences for their discoveries related to multiple sclerosis disease ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive ...

Tolebrutinib, a novel BTK inhibitor that targets neuroinflammation, slowed disability progression by 31% in nrSPMS, a phase 3 ...